AstraZeneca and Daiichi Sankyo ADC cancer drug approved for fifth indication in China.

Ascertained from AstraZeneca, its injection of trastuzumab deruxtecan has been approved for a fifth new indication in China, as a monotherapy for the treatment of adult patients with unresectable or metastatic hormone receptor-positive, HER2 low-expressing or HER2 non-expressing breast cancer that has progressed following at least one endocrine therapy for metastatic disease. Trastuzumab deruxtecan is a HER2-targeted DXd antibody-drug conjugate developed by Daiichi Sankyo and co-commercialized by AstraZeneca and Daiichi Sankyo. It was previously approved in China for the treatment of breast cancer, lung cancer, and other tumors.